title: What is the most important approach in current drug discovery: doing the right things or doing things right?
abstract: Doing the right things or doing things right: what is the most important focus for current drug discovery to secure delivery of new drugs of sustainable value to patients, healthcare professionals and healthcare providers? Some of the challenges faced today in drug discovery are addressed here: the relationship between R&D speed, cost and quality; how selection of performance metrics can affect the quality of the R&D output; the importance of leadership and management; how process orientation can affect, for example, creativity and innovation; the importance of selecting the right pharmacologic target and the right chemical lead; and why the use of drug-target kinetic and thermodynamic data to drive lead selection and lead optimization could increase success rates.
authors.affiliation: AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden. Thomas.Elebring@astrazeneca.com
authors.forename: Thomas
authors.initials: T
authors.lastname: Elebring
authors.forename: Adrian
authors.initials: A
authors.lastname: Gill
authors.forename: Alleyn T
authors.initials: AT
authors.lastname: Plowright
mesh_terms: D003365:Costs and Cost Analysis; D015195:Drug Design; D055808:Drug Discovery / Q000191:economics / Q000379:methods*; D004345:Drug Industry / Q000191:economics / Q000379:methods* / Q000458:organization & administration; D006801:Humans; D007857:Leadership; D058990:Molecular Targeted Therapy; D009936:Organizational Innovation; D012106:Research / Q000191:economics / Q000458:organization & administration / Q000592:standards; D013816:Thermodynamics; D013997:Time Factors